AstraZeneca Tagrisso, Pfizer Xalkori Stand Out Among US FDA’s Single-Arm Oncology Approvals, JAMA Suggests
Only two US approvals based on single-arm trials met the European Society for Medical Oncology’s threshold for substantial clinical benefit, according to an analysis of cancer drugs approved over a decade.
You may also be interested in...
US FDA cancer chief Rick Pazdur plans to send industry to ‘rehab’ with Project Frontrunner, which will push for development of cancer drugs in randomized controlled trials in earlier disease. Goal is to reduce time of uncertainty between accelerated approval and confirmatory evidence.
FOCR study suggests overall survival for PD-1s seen in real-world datasets is similar to results from clinical trials.
Round-up of commentary on oncology drug value and costs during the American Society for Clinical Oncology annual meeting, including value frameworks, ways to lower drug costs and payer data.